Lung immunity is an area of a scientific excellence in our respiratory research group. We discover disease modifying therapies that reverse the immunological imbalance in the lung, focussing on immunomodulation, lung microbiome and cell metabolism and plasticity.
Once considered merely a physical barrier to the environment, we now better understand the active role of the lung epithelium. Our research goal in lung epithelium biology and lung regeneration is to restore normal tissue architecture and lung epithelial integrity and investigate the mechanisms of cell senescence in the pulmonary epithelium within populations at risk for COPD and IPF. Along with targeting aberrant epithelial biology, lung fibrosis and restoring an appropriate immune response in the lung, we hope to promote lung regeneration in all chronic lung diseases.
We have recently announced the formation of a new Target and Translational Science department. This state of the art department will leverage contemporary genomics and other ‘omics, clinical back translation, artificial intelligence and data science to strengthen our target science and human validation approaches, translate model system findings into man to increase confidence in our portfolio, deliver precision medicine hypotheses aligned to development plans and work closely with our Early Clinical Development colleagues to build clinical disease knowledge.
Who we look for
If you want to be part of bringing new innovative respiratory medicines to patients and are looking to develop and build your scientific expertise and exposure, AstraZeneca can offer you a unique collaborative environment in which to succeed. To further strengthen our expertise and capacity in each of these strategic research areas we are currently recruiting a number of world-class scientists in the following broad respiratory areas:
Medicinal, Analytical and Computational Chemists
Experienced drug discovery and early development project leaders
Translational Science Leads
Target Validation Leads
Biomarker Discovery Scientists
Target science leads
Inhalation drug discovery and development experts